ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Amicus Therapeutics, Inc." (FOLD) Report Updated: Sep 19, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Amicus Therapeutics, Inc." (FOLD)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: DMPI,EXEL,SPHS,MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Amicus Therapeutics, Inc."© quotemedia

Company Profile

Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs include next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has completed two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson's disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat. Amicus Therapeutics, Inc. was incorporated in 2002 and is based in Cranbury, New Jersey.